

Breast Cancer Er-Positive Breast Cancer HER-2 Negative

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

Trial Status
Terminated

Trial Runs In
5 Countries

Trial Identifier
NCT03584009 2017-005118-74
WO40181

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase II, multicenter, open-label, randomized study to compare the efficacy of venetoclax in combination with fulvestrant compared with fulvestrant alone in women with ER+, HER2-negative, locally advanced or Metastatic Breast Cancer (MBC) who experienced disease recurrence or progression during or after treatment with CDK4/6i therapy for at least 8 weeks. As of 9th October 2020, participants in the Venetoclax + Fulvestrant arm, have all discontinued Venetoclax treatment and have continued on Fulvestrant treatment alone.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT03584009 2017-005118-74 WO40181
Trial Identifiers

Eligibility Criteria:

Gender
Female

Age
>= 18 Years

Healthy Volunteers
No
